Natasha Barrow

2 days ago | insights.citeline.com | Marion Webb |Brian Bossetta |Natasha Barrow |Elizabeth Orr

Digital Health Roundup: Synchron Syncs With Apple, Ketryx’s AI Agents, AdvaMed’s AI RoadMapIn this week's Digital Health Roundup, MedTech Insight's Shubham Singh explores how Ketryx's launch of validated AI agents could reshape compliance automation in medtech. Marion Webb highlights news from BCI makers Synchron, Axoft and Subsense. Elizabeth Orr discusses AI advances at the FDA.

4 days ago | insights.citeline.com | Natasha Barrow

First AI Breast Cancer Prediction Platform Receives FDA Authorization Clairity Breast Predicts Women’s Five-Year Future Risk Of Breast CancerClairity’s "first-in-class" mammography-based AI screening tool, Clairity Breast, provides "equitable risk assessments," expanding access to lifesaving early detection for breast cancer, said company founder Connie Lehman.

5 days ago | insights.citeline.com | Natasha Barrow

SAGA Diagnostics Launches Early Breast Cancer MRD Detection Test In US ‘Best-In-Class Clinical Performance’: 100% Sensitivity And 100% Specificity SAGA Diagnostics has launched its breast cancer residual and recurrence detection test – Pathlight – in the US. The test’s ultrahigh sensitivity and specificity is rare to see in oncology, the company claimed.

1 week ago | insights.citeline.com | Natasha Barrow

ConcertAI Launches Generative AI-Powered Precision Suite Three New Applications Support Health Economics, Clinical Trial And Commercialization Teams Valued at over $1.9bn, ConcertAI is building on its pre-existing multi-agentic AI SaaS solution CARAai to bring life science customers the new Precision suite of applications: Precision Explorer, Precision Trials, Precision GTM and Precision360.

1 week ago | insights.citeline.com | Natasha Barrow

Roche Diagnostics Day 2025: ‘We Need To Become A Leader In Decentralized Testing’‘Axelios’: Roche’s Sequencing Solution Planned For 2026 Launch Roche aims to grow its diagnostics sales by mid to high single digits, said CEO of Roche Diagnostics Matt Sause. The company unveiled the Axelios synthesis and sequencing solution and discussed its “long-term commitment” to China, as well as its business strategy for the next five years.